CA2472241A1 - The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus - Google Patents
The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus Download PDFInfo
- Publication number
- CA2472241A1 CA2472241A1 CA002472241A CA2472241A CA2472241A1 CA 2472241 A1 CA2472241 A1 CA 2472241A1 CA 002472241 A CA002472241 A CA 002472241A CA 2472241 A CA2472241 A CA 2472241A CA 2472241 A1 CA2472241 A1 CA 2472241A1
- Authority
- CA
- Canada
- Prior art keywords
- melagatran
- pharmaceutically
- cells
- islets
- acceptable derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 title claims abstract description 87
- 229960002137 melagatran Drugs 0.000 title claims abstract description 84
- 238000011282 treatment Methods 0.000 title claims abstract description 32
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 title claims abstract description 21
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 title claims abstract description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 44
- 238000002054 transplantation Methods 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 41
- 210000004027 cell Anatomy 0.000 claims description 37
- 210000004369 blood Anatomy 0.000 claims description 30
- 239000008280 blood Substances 0.000 claims description 30
- 102000004877 Insulin Human genes 0.000 claims description 22
- 108090001061 Insulin Proteins 0.000 claims description 22
- 229940125396 insulin Drugs 0.000 claims description 22
- 210000004153 islets of langerhan Anatomy 0.000 claims description 22
- 239000000651 prodrug Substances 0.000 claims description 14
- 229940002612 prodrug Drugs 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 10
- 239000002243 precursor Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 210000000130 stem cell Anatomy 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000009877 rendering Methods 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 239000000306 component Substances 0.000 description 16
- 230000010412 perfusion Effects 0.000 description 13
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- 230000004913 activation Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 230000015271 coagulation Effects 0.000 description 6
- 238000005345 coagulation Methods 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 108010041201 prothrombin fragment 1 Proteins 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 239000004019 antithrombin Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000024203 complement activation Effects 0.000 description 4
- 230000004154 complement system Effects 0.000 description 4
- 238000011532 immunohistochemical staining Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 108010094028 Prothrombin Proteins 0.000 description 3
- 102100027378 Prothrombin Human genes 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 229940039716 prothrombin Drugs 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 238000011891 EIA kit Methods 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 2
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 2
- 108060005987 Kallikrein Proteins 0.000 description 2
- 102000001399 Kallikrein Human genes 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920000392 Zymosan Polymers 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- -1 cyclohexylglycinyl Chemical group 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- UOFGSWVZMUXXIY-UHFFFAOYSA-N 1,5-Diphenyl-3-thiocarbazone Chemical compound C=1C=CC=CC=1N=NC(=S)NNC1=CC=CC=C1 UOFGSWVZMUXXIY-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 229940124073 Complement inhibitor Drugs 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940039088 kininogenase Drugs 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001019 normoglycemic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0200198A SE0200198D0 (sv) | 2002-01-23 | 2002-01-23 | New use |
| SE0200198-0 | 2002-01-23 | ||
| PCT/SE2003/000087 WO2003061682A1 (en) | 2002-01-23 | 2003-01-21 | The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2472241A1 true CA2472241A1 (en) | 2003-07-31 |
Family
ID=20286751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002472241A Abandoned CA2472241A1 (en) | 2002-01-23 | 2003-01-21 | The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7045502B2 (OSRAM) |
| EP (1) | EP1469874A1 (OSRAM) |
| JP (1) | JP2005516035A (OSRAM) |
| KR (1) | KR20040075096A (OSRAM) |
| CN (1) | CN100430089C (OSRAM) |
| BR (1) | BR0306798A (OSRAM) |
| CA (1) | CA2472241A1 (OSRAM) |
| IL (1) | IL162853A0 (OSRAM) |
| MX (1) | MXPA04007192A (OSRAM) |
| NO (1) | NO20043483L (OSRAM) |
| NZ (1) | NZ533749A (OSRAM) |
| SE (1) | SE0200198D0 (OSRAM) |
| WO (1) | WO2003061682A1 (OSRAM) |
| ZA (1) | ZA200405342B (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0200198D0 (sv) * | 2002-01-23 | 2002-01-23 | Astrazeneca Ab | New use |
| JP6155187B2 (ja) | 2010-03-30 | 2017-06-28 | ヴァーセオン コーポレイション | トロンビンの阻害剤としての多置換芳香族化合物 |
| WO2014145986A1 (en) | 2013-03-15 | 2014-09-18 | Verseon, Inc. | Multisubstituted aromatic compounds as serine protease inhibitors |
| ES2791749T3 (es) | 2013-03-15 | 2020-11-05 | Verseon Corp | Halogenopirazoles como inhibidores de la trombina |
| KR20170048410A (ko) | 2014-09-17 | 2017-05-08 | 베르선 코포레이션 | 세린 프로테아제 저해제로서의 피라졸릴-치환된 피리돈 화합물 |
| AU2016224974B2 (en) | 2015-02-27 | 2019-09-26 | Verseon Corporation | Substituted pyrazole compounds as serine protease inhibitors |
| IL280078B2 (en) | 2018-07-13 | 2024-04-01 | Verseon Int Corporation | Thrombin inhibitors, formulations, and uses thereof |
| AU2022325955A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
| JP2025508720A (ja) | 2022-02-17 | 2025-04-10 | サナ バイオテクノロジー，インコーポレイテッド | 遺伝子操作されたｃｄ４７タンパク質及びその使用関連出願の相互参照 |
| AU2024264889A1 (en) | 2023-05-03 | 2025-11-13 | Sana Biotechnology, Inc. | Methods of dosing and administration of engineered islet cells |
| CN121604968A (zh) | 2023-05-22 | 2026-03-03 | 萨那生物科技公司 | 递送胰岛细胞的方法及相关方法 |
| IL326710A (en) | 2023-08-23 | 2026-04-01 | Sana Biotechnology Inc | Modified CD47 proteins and their uses |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9301916D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
| TW541316B (en) | 1995-12-21 | 2003-07-11 | Astrazeneca Ab | Prodrugs of thrombin inhibitors |
| SE9900070D0 (sv) | 1999-01-13 | 1999-01-13 | Astra Ab | New use |
| SE523817C2 (sv) | 1999-02-05 | 2004-05-18 | Corline Systems Ab | Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler |
| US6462021B1 (en) | 2000-11-06 | 2002-10-08 | Astrazeneca Ab | Use of low molecular weight thrombin inhibitor |
| SE0200198D0 (sv) * | 2002-01-23 | 2002-01-23 | Astrazeneca Ab | New use |
-
2002
- 2002-01-23 SE SE0200198A patent/SE0200198D0/xx unknown
-
2003
- 2003-01-21 MX MXPA04007192A patent/MXPA04007192A/es unknown
- 2003-01-21 EP EP03701203A patent/EP1469874A1/en not_active Withdrawn
- 2003-01-21 JP JP2003561625A patent/JP2005516035A/ja active Pending
- 2003-01-21 CN CNB038026740A patent/CN100430089C/zh not_active Expired - Fee Related
- 2003-01-21 IL IL16285303A patent/IL162853A0/xx unknown
- 2003-01-21 BR BR0306798-0A patent/BR0306798A/pt not_active IP Right Cessation
- 2003-01-21 NZ NZ533749A patent/NZ533749A/en unknown
- 2003-01-21 US US10/502,069 patent/US7045502B2/en not_active Expired - Fee Related
- 2003-01-21 WO PCT/SE2003/000087 patent/WO2003061682A1/en not_active Ceased
- 2003-01-21 KR KR10-2004-7011228A patent/KR20040075096A/ko not_active Withdrawn
- 2003-01-21 CA CA002472241A patent/CA2472241A1/en not_active Abandoned
-
2004
- 2004-07-05 ZA ZA2004/05342A patent/ZA200405342B/en unknown
- 2004-08-20 NO NO20043483A patent/NO20043483L/no not_active Application Discontinuation
-
2006
- 2006-02-24 US US11/362,890 patent/US20060148720A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20060148720A1 (en) | 2006-07-06 |
| US7045502B2 (en) | 2006-05-16 |
| US20050090424A1 (en) | 2005-04-28 |
| ZA200405342B (en) | 2005-09-28 |
| IL162853A0 (en) | 2005-11-20 |
| CN1729010A (zh) | 2006-02-01 |
| SE0200198D0 (sv) | 2002-01-23 |
| NZ533749A (en) | 2006-02-24 |
| KR20040075096A (ko) | 2004-08-26 |
| BR0306798A (pt) | 2004-12-07 |
| WO2003061682A1 (en) | 2003-07-31 |
| CN100430089C (zh) | 2008-11-05 |
| JP2005516035A (ja) | 2005-06-02 |
| EP1469874A1 (en) | 2004-10-27 |
| MXPA04007192A (es) | 2004-10-29 |
| NO20043483L (no) | 2004-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ozmen et al. | Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation | |
| Markmann et al. | Insulin independence following isolated islet transplantation and single islet infusions | |
| Nijhoff et al. | Glycemic stability through islet-after-kidney transplantation using an alemtuzumab-based induction regimen and long-term triple-maintenance immunosuppression | |
| JP4972113B2 (ja) | デキストラン硫酸エステルを含有する新規治療薬 | |
| US7045502B2 (en) | Use of melagatran for the manufacture of a medicament for the treatment of Type 1 diabetes mellitus | |
| Yan et al. | The influence of microenvironment on survival of intraportal transplanted islets | |
| Mühlbacher et al. | Blockade of HLA antibody-triggered classical complement activation in sera from subjects dosed with the anti-C1s monoclonal antibody TNT009—results from a randomized first-in-human phase 1 trial | |
| Vasanthan et al. | Periodontal treatment considerations for cell transplant and organ transplant patients. | |
| Takita et al. | Variables associated with islet yield in autologous islet cell transplantation for chronic pancreatitis | |
| AU2003202192A1 (en) | The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus | |
| US20050255111A1 (en) | Use of an inhibitor or antagonist against tissue factor | |
| Yoshimatsu et al. | The impact of allogenic blood transfusion on the outcomes of total pancreatectomy with islet autotransplantation | |
| Berney et al. | Islet Allotransplantation | |
| Mattke | Targeting Toll-Like Receptor 4 Related Inflammation Using Small Molecule, TAK-242, to Attenuate Inflammatory Damage in Pancreatitis and Islet Transplantation | |
| Mineo et al. | Islet and pancreas transplantation | |
| Saudek | Pancreatic Islet Transplantation | |
| WO1996016653A1 (en) | Immunorejection inhibitor | |
| Pattewar et al. | A case study to evaluate the effect of Punarnava Varun Kwatha in the management of Mutrashmari (urolithiasis) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |